Lung Tumors Trigger Cachexia by Hacking Nerve Signals

Cancer cachexia is a severe syndrome affecting a large proportion of patients with advanced-stage cancer, leading to rapid weight loss and loss of appetite. For many years, it was believed that this condition primarily arose because molecules secreted by the tumor into the bloodstream triggered systemic inflammation. However, a new study published in the journal Science reveals that certain types of lung cancer use the nervous system to initiate this process. The researchers discovered that tumors secrete a molecule called prostaglandin E2 (PGE2), which activates sensory neurons in the lungs. These neurons send direct signals through the nervous system to brainstem regions that regulate appetite. This finding radically changes the current perspective on the underlying mechanisms of cancer-related fatigue and weight loss.

One of the most surprising findings of the study was related to the dietary habits applied to prevent weight loss in patients. Traditionally, clinicians recommended high-calorie and high-fat diets to help cancer patients maintain their weight. However, experiments conducted on mice showed that high-fat diets, particularly those rich in animal fats, accelerated cachexia. The researchers determined that this was because animal fats increase the production of PGE2 in tumors. High fat consumption exacerbates inflammatory signals, further suppressing patients' appetites and worsening their condition. This unexpected result highlights the need to re-evaluate nutritional recommendations for cancer patients.

Scientists compared this neural manipulation mechanism of tumors to the behavioral effects of respiratory tract infections. During influenza or bacterial lung infections, sensory neurons in the lungs detect inflammation and send direct warnings to the brain, causing the patient to lose their appetite. Lung tumors similarly deceive the body, utilizing this same biological pathway even in the absence of an infection to suppress the patient's instinct to eat. In this process, rather than circulating factors in the blood, the direct neural communication between the tumor and the brain is held responsible. The findings prove that tumors exploit the body's own defense and sickness behavior mechanisms to their advantage.

To prove this theory, the research team disrupted the communication between the lungs and the brain using two different methods. In the first experiment, a branch of the mice's vagus nerve was surgically severed, and this intervention notably reduced the loss of appetite. Subsequently, using an advanced neuroscience technique called chemogenetics, only the lung sensory neurons that send signals to the brain were selectively deactivated. When these neurons were silenced, the mice were observed to maintain their normal eating, drinking, and moving behaviors, as if they were not suffering from cachexia. These results clearly demonstrated that the wasting syndrome caused by cancer can be targeted and halted through the nervous system.

These findings open exciting new therapeutic doors for the treatment of cancer cachexia. While surgically cutting the vagus nerve is not a practical treatment method, scientists are focusing on pharmacological solutions. For instance, instead of broad-spectrum drugs like aspirin or ibuprofen, the development of drugs that specifically block prostaglandin receptors in sensory neurons is being planned. Additionally, testing FDA-approved neuromodulation devices—which are used to electrically stimulate the vagus nerve—in cancer patients is also on the agenda. Experts believe that these innovative approaches could improve the quality of life for cancer patients and facilitate their treatment processes in the future.